Comparative Pharmacology
Head-to-head clinical analysis: KIMIDESS versus NYLIA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KIMIDESS versus NYLIA 1 35.
KIMIDESS vs NYLIA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
Combination oral contraceptive consisting of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial lining.
5 mg orally once daily, with or without food.
One tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no medication. Continuous sequential regimen.
None Documented
None Documented
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Norethindrone: 5-14 hours (mean ~8 hours); Ethinyl estradiol: 7-36 hours (mean ~14 hours). Clinically, steady-state is achieved within 5-7 days.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Renal: 40-60% (as metabolites, mainly ethinyl estradiol glucuronide and sulfate conjugates and norethindrone metabolites). Biliary/fecal: 30-50% (as conjugates and metabolites).
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive